Triple-negative breast cancer constitutes~ 15% of all breast cancer subtypes. Because of the
negative hormone receptor and human epidermal growth factor receptor 2 status, therapy is …

Triple negative breast cancer (TNBC) is still associated with grave prognosis, especially
compared to other breast cancer subtypes. Advances in medical science have improved our …

Triple-negative breast cancer (TNBC) refers to cancers that are low in expression of the
estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor …

The treatment of triple-negative breast cancer remains chemotherapy based and lacks
targeted drugs. However, immunotherapy combinations have shown promising activity …

Immunotherapy comprises a promising new era in cancer therapy. Immune checkpoint
inhibitors targeting either the programmed death (PD)-1 receptor or its ligand PD-L1 were …

Patients with breast cancer along with metastatic estrogen and progesterone receptor
(ER/PR)-and human epidermal growth factor receptor 2 (HER2)-negative tumors are …

Triple-negative breast cancer (TNBC) is a very heterogeneous and aggressive breast
cancer subtype with a high risk of mortality, even if diagnosed early. The mainstay of early …

Introduction: Breast cancer is the most common malignancy in women in the United States
and triple-negative breast cancer (TNBC) accounts for 15–20%. The standard of care for …

Triple-negative breast cancer (TNBC), a complex subtype of breast cancer that lacks
estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor …

TNBC is one of the most complicated types of breast cancer to treat. It is generally
diagnosed based on the absence of three receptors: estrogen, progesterone, and human …